Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Drug Use To Receive CMS Scrutiny, McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Centers for Medicare & Medicaid Services plans to improve its collaborations with outside experts to better understand Rx drug use among seniors. The agency will share the information with providers.

You may also be interested in...

CMS Off-Label Cancer Drug Policy Will Have "Very Narrow" Focus

Policy decision for covering unapproved, non-compendial indications for cancer drugs is still pending, but will not mean a "sea change" in reimbursement, agency official says. Real issue is "unorganized" approach to off-label use as a whole in the U.S.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts